Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inhibikase Therapeutics Inc
(NQ:
IKT
)
1.460
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inhibikase Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...
Via
Benzinga
Looking Into Inhibikase Therapeutics's Return On Capital Employed
December 27, 2022
Via
Benzinga
Dow Surges 400 Points; Crude Oil Down 1%
November 07, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday.
Via
Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
November 07, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday.
Via
Benzinga
Recap: Inhibikase Therapeutics Q1 Earnings
May 16, 2022
Inhibikase Therapeutics (NASDAQ:IKT) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For May 16, 2022
May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
November 16, 2022
Upgrades
Via
Benzinga
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket
August 29, 2022
Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q.
Via
Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
November 16, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
November 15, 2022
Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Gainers
Via
Benzinga
Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
August 26, 2022
The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug...
Via
Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
November 07, 2022
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.
Via
Benzinga
Inhibikase Therapeutics: Q2 Earnings Insights
August 12, 2022
Inhibikase Therapeutics (NASDAQ:IKT) reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For August 12, 2022
August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.
Via
Benzinga
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
August 30, 2022
Gainers
Via
Benzinga
Earnings Preview: Inhibikase Therapeutics
August 11, 2022
Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement.
Via
Benzinga
Why Chimerix Is Trading Higher By Over 19%, Here Are 53 Stocks Moving In Monday's Mid-Day Session
August 29, 2022
Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed a Master Services Agreement with Estonia-based Activate Health OÜ.
Via
Benzinga
24 Stocks Moving in Wednesday's Pre-Market Session
June 15, 2022
Gainers Boxed, Inc. (NYSE: BOXD) rose 38.3% to $1.95 in pre-market trading. Boxed reported that Director Andrew Pearson bought 150,000 shares at an average price of $1.82 per share.
Via
Benzinga
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
August 16, 2022
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Via
Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
August 15, 2022
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New...
Via
Benzinga
Inhibikase Therapeutics's Return On Capital Employed Overview
April 01, 2022
Inhibikase Therapeutics (NASDAQ:IKT) brought in sales totaling $1.94 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.76%, resulting in a loss of $5.04...
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 31, 2022
March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Via
Benzinga
Earnings Outlook For Inhibikase Therapeutics
March 30, 2022
Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Inhibikase Targets A Substantial Market Following Presentation of Results Presented at The Barcelona Conference
March 28, 2022
The upcoming trial results are expected to show an excellent safety profile of the drug and perhaps some biomarkers that translate into efficacy.
Via
Talk Markets
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.